Lactobacilli as live vaccine delivery vectors: Progress and prospects

Trends in Biotechnology

Volumn 20, Issue 12, 2002, Pages 508-515

  Seegers, Jos F M L ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CLONING; IMMUNOLOGY; VACCINES;

VACCINATION;

BIOTECHNOLOGY;

CYTOKINE; DRUG CARRIER; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; TETANUS TOXIN;

BIOTECHNOLOGY; VACCINATION;

CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOMODULATION; LACTIC ACID BACTERIUM; LACTOBACILLUS; MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; VACCINATION;

BACTERIAL VACCINES; CLONING, MOLECULAR; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL DISEASES; HUMANS; LACTOBACILLUS; PEPTIDE FRAGMENTS; PROBIOTICS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY; TETANUS TOXIN; VACCINATION; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); LACTOBACILLUS; NEGIBACTERIA;

EID: 0036890247     PISSN: 01677799     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-7799(02)02075-9     Document Type: Review

References (64)

1. Kruger C., et al. In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat. Biotechnol. 20:2002;702-706.
2. Kruisselbrink A., et al. Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses. Clin. Exp. Immunol. 126:2001;2-8.
3. McGhee J.R., Mestecky J. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect. Dis. Clin. North Am. 4:1990;315-341.
4. Ryan E.J., et al. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol. 19:2001;293-304.
5. Medina E., Guzman C.A. Use of live bacterial vaccine vectors for antigen delivery: Potential and limitations. Vaccine. 19:2001;1573-1580.
6. Attridge S.R., et al. Oral delivery of foreign antigens by attenuated Salmonella: Consequences of prior exposure to the vector strain. Vaccine. 15:1997;155-162.
7. Ribeiro L.A., et al. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: A first step towards food-grade live vaccines against brucellosis. Appl. Environ. Microbiol. 68:2002;910-916.
8. Lee M.H., et al. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine. 19:2001;3927-3935.
9. Oggioni M.R., et al. Antigenicity and immunogenicity of the V3 domain of HIV type 1 glycoprotein 120 expressed on the surface of Streptococcus gordonii. AIDS Res. Hum. Retroviruses. 15:1999;451-459.
10. Maggi T., et al. Expression of measles virus antigens in Streptococcus gordonii. New Microbiol. 23:2000;119-128.
11. Zegers N.D., et al. Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: Towards the development of an oral vaccine against anthrax. J. Appl. Microbiol. 87:1999;309-314.
12. Enouf V., et al. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl. Environ. Microbiol. 67:2001;1423-1428.
13. Shaw D.M., et al. Engineering the microflora to vaccinate the mucosa: Serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli. Immunology. 100:2000;510-518.
14. Grangette C., et al. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect. Immun. 69:2001;1547-1553.
15. Marteau P.R. Probiotics in clinical conditions. Clin. Rev. Allergy. 22:2002;255-273.
16. Dunne C., et al. Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. Antonie Van Leeuwenhoek. 76:1999;279-292.
17. Kalliomaki M., et al. Probiotics in primary prevention of atopic disease: A randomised placebo-controlled trial. Lancet. 357:2001;1076-1079.
18. Maassen C.B., et al. Instruments for oral disease-intervention strategies: Recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis. Vaccine. 17:1999;2117-2128.
19. Meydani S.N., Ha W.K. Immunologic effects of yogurt. Am. J. Clin. Nutr. 71:2000;861-872.
20. Gronlund M.M., et al. Importance of intestinal colonisation in the maturation of humoral immunity in early infancy: A prospective follow up study of healthy infants aged 0-6 months. Arch. Dis. Child. Fetal Neonatal Ed. 83:2000;F186-F192.
21. Kaila M., et al. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr. Res. 32:1992;141-144.
22. Haller D., et al. Activation of human NK cells by staphylococci and lactobacilli requires cell contact-dependent costimulation by autologous monocytes. Clin. Diagn. Lab. Immunol. 9:2002;649-657.
23. Cross M.L., et al. Dietry intake of Lactobacillus rhamnosus HNOO1 enhances production of both Th1 and Th2 cytokines in antigen-primed mice. Med. Microbiol. Immunol. 191:2002;49-53.
24. Maassen C.B., et al. Strain-dependent induction of cytokine profiles in the gut by orally administered Lactobacillus strains. Vaccine. 18:2000;2613-2623.
25. Pouwels P.H., et al. The potential of Lactobacillus as a carrier for oral immunization: development and preliminary characterization of vector systems for targeted delivery of antigens. J. Biotechnol. 44:1996;183-192.
26. Christensen H.R., et al. Lactobacilli differentially modulate expression of cytokines and maturation surface markers in murine dendritic cells. J. Immunol. 168:2002;171-178.
27. Jepson M.A., Clark M.A. Studying M cells and their role in infection. Trends Microbiol. 6:1998;359-365.
28. Rescigno M., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2:2001;361-367.
29. Medzhitov R., Janeway C.A.J. Innate immunity: the virtues of a nonclonal system of recognition. Cell. 91:1997;295-298.
30. Janeway C.A.J., Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 20:2002;197-216.
31. Harris N.L., Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol. Cell. Biol. 77:1999;304-311.
32. Neish A.S., et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science. 289:2000;1560-1563.
33. Steidler L., et al. Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine. Infect. Immun. 66:1998;3183-3189.
34. Kleerebezem M., et al. Controlled gene expression systems for lactic acid bacteria: Transferable nisin-inducible expression cassettes for Lactococcus, Leuconostoc, and Lactobacillus spp. Appl. Environ. Microbiol. 63:1997;4581-4584.
35. Pavan S., et al. Adaptation of the nisin-controlled expression system in Lactobacillus plantarum: A tool to study in vivo biological effects. Appl. Environ. Microbiol. 66:2000;4427-4432.
36. Lokman B.C., et al. Regulation of expression of the Lactobacillus pentosus xylAB operon. J. Bacteriol. 179:1997;5391-5397.
37. Reveneau N., et al. Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine. 20:2002;1769-1777.
38. Pouwels P.H., et al. Lactobacilli as vehicles for targeting antigens to mucosal tissues by surface exposition of foreign antigens. Methods Enzymol. 336:2001;369-389.
39. McCracken A., Timms P. Efficiency of transcription from promoter sequence variants in Lactobacillus is both strain and context dependent. J. Bacteriol. 181:1999;6569-6572.
40. Kane J.F. Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr. Opin. Biotechnol. 6:1995;494-500.
41. Pouwels P.H., Leunissen J.A. Divergence in codon usage of Lactobacillus species. Nucleic Acids Res. 22:1994;929-936.
42. Wells J.M., et al. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge. Mol. Microbiol. 8:1993;1155-1162.
43. Fairweather N.F., et al. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli. Infect. Immun. 55:1987;2541-2545.
44. Galen J.E., et al. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens. Vaccine. 15:1997;700-708.
45. Miyaji E.N., et al. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect. Immun. 69:2001;869-874.
46. Stevenson A., Roberts M. Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens. Vaccine. 20:2002;2325-2335.
47. Reveneau N., et al. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis. Vaccine. 20:2001;926-933.
48. Medaglini D., et al. Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice. Vaccine. 19:2001;1931-1939.
49. Isticato R., et al. Surface display of recombinant proteins on Bacillus subtilis spores. J. Bacteriol. 183:2001;6294-6301.
50. Robinson K., et al. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis. Nat. Biotechnol. 15:1997;653-657.
51. Heinzel F.P., et al. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 169:1989;59-72.
52. Rossi-Bergmann B., et al. TH1 and TH2 T-cell subsets are differentially activated by macrophages and B cells in murine leishmaniasis. Infect. Immun. 61:1993;2266-2269.
53. Scheppler L., et al. Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Vaccine. 20:2002;2913-2920.
54. O'Hagan D.T., et al. Recent developments in adjuvants for vaccines against infectious diseases. Biomol. Eng. 18:2001;69-85.
55. Cano F., et al. A surface-displayed cholera toxin B peptide improves antibody responses using food-grade staphylococci for mucosal subunit vaccine delivery. FEMS Immunol. Med. Microbiol. 25:1999;289-298.
56. Corinti S., et al. Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4+ T lymphocytes. J. Immunol. 163:1999;3029-3036.
57. Corinti S., et al. Human dendritic cells are superior to B cells at presenting a major histocompatibility complex class II-restricted heterologous antigen expressed on recombinant Streptococcus gordonii. Infect. Immun. 68:2000;1879-1883.
58. Steidler L., et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 289:2000;1352-1355.
59. Perdigon G., et al. Study of the possible mechanisms involved in the mucosal immune system activation by lactic acid bacteria. J. Dairy. Sci. 82:1999;1108-1114.
60. Geoffroy M.C., et al. Use of green fluorescent protein to tag lactic acid bacterium strains under development as live vaccine vectors. Appl. Environ. Microbiol. 66:2000;383-391.
61. Simecka J.W. Mucosal immunity of the gastrointestinal tract and oral tolerance. Adv. Drug Deliv. Rev. 34:1998;235-259.
62. Iwaki M., et al. Oral immunization with recombinant Streptococcus lactis carrying the Streptococcus mutans surface protein antigen gene. Infect. Immun. 58:1990;2929-2934.
63. Dieye Y., et al. Design of a protein-targeting system for lactic acid bacteria. J. Bacteriol. 183:2001;4157-4166.
64. Smit E., et al. The S-layer protein of Lactobacillus acidophilus ATCC 4356: identification and characterisation of domains responsible for S-protein assembly and cell wall binding. J. Mol. Biol. 305:2001;245-257.